Disease · MONDO_0001103

giardiasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. giardiasis. Diseases, record MONDO_0001103. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001103

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: giardiasis; Open Targets
Open Targets ID: MONDO_0001103; Open Targets
Other names: Giardia infection, beaver fever; Open Targets
Disease Ontology: DOID:10718; Disease Ontology
MeSH: D005873; MeSH
Highest stage of its drugs: Phase 2/3, for 2 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
20-HYDROXYECDYSONE	CHEMBL224128	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
AURANOFIN	CHEMBL1366	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ALBENDAZOLE	CHEMBL1483	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
SECNIDAZOLE	CHEMBL498847	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02736968	Auranofin for Giardia Protozoa	Phase 2	93	2023-01-26	Amoebic Dysentery, Giardiasis	AURANOFIN	Its record names the disease	ClinicalTrials.gov
NCT00607074	Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh	Not applicable	410		Giardiasis	ALBENDAZOLE, SECNIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT04827537	Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone	Phase 2/3	200		Giardia Lamblia Infection	20-HYDROXYECDYSONE, METRONIDAZOLE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Symptomatic Giardia- Auranofin vs Symptomatic Giardia- Placebo: Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)	28 of 29	28 of 29	58	NCT02736968	Trial comparisons
Asymptomatic Giardia- Auranofin vs Asymptomatic Giardia- Placebo: Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)	6 of 14	6 of 14	28	NCT02736968	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
18789466	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001103

GET https://conductscience.org/api/diseases/v1/MONDO_0001103/drugs

API reference For AI assistants